您好,欢迎来到仪器设备网! [登录] [免费注册]
仪器设备网
位置:首页 > 产品库 > 2-cyano-Pyrimidine
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
2-cyano-Pyrimidine
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
2-cyano-Pyrimidine图片
CAS NO:14080-23-0
包装与价格:
包装价格(元)
5g电议
10g电议

产品介绍

化学性质

StorageStore at -20°C
M.Wt124.1
Cas No.14080-23-0
FormulaC5H3N3
Solubilityinsoluble in EtOH; ≥24.2 mg/mL in H2O with ultrasonic; ≥8.2 mg/mL in DMSO
Chemical Name2-pyrimidinecarbonitrile
Canonical SMILESNCc1ncccn1
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 170 nM

2-cyano-Pyrimidine is a cathepsin K inhibitor.

Cathepsin K is a protease defined by its high specificity for kinins, which is involved in bone resorption. Cathepsin K's ability to catabolize collagen, elastin, and gelatin allow it to break down bone and cartilage. Such catabolic activity is also partially responsible for the loss of lung elasticity and recoil in emphysema. Therefore, inhibitors of Cathepsin K are showing great potential in the treatment of osteoporosis.

In vitro: 2-cyano-Pyrimidine was identified as a cathepsin K inhibitor whose basic structure and derivatives have been evaluated for the treatment of osteoporosis. Enzymatic study showed that 2-cyano-Pyrimidine had an IC50 value of 170 nM for inhibition of cathepsin K, elevated activity of which has been linked to the formation of osteoporosis and arthritis. Moreover, Cathepsin K was found to be a lysosomal cysteine protease found in osteoclasts. [1,2].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Altmann, E. ,Aichholz, R.,Betschart, C., et al. 2-cyano-pyrimidines: A new chemotype for inhibitors of the cysteine protease cathepsin K. Journal of Medicinal Chemistry 50(4), 591-594 (2007).
[2] Rankovic Z et al.  Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7.